U.S. stock market update: 180 Life Sciences down 11.50%

U.S. Stock Market Midday Update 180 Life Sciences fell 11.50%. Based on recent important news: On August 14, 180 Life Sciences announced a potential sale of up to $500 million in common stock, leading to a 11.50% drop in stock price. On August 12, billionaire Peter Thiel disclosed a 7.5% stake in the company, driving the stock price up. On August 12, the company completed a $156 million private placement, causing the stock price to surge 54%. Stocks with High Trading Volume in the Industry AbbVie rose 0.38%, with increased trading volume. Based on recent important news: On August 13, AbbVie reported second-quarter results, with revenue up 6.6% year-over-year, exceeding market expectations, and adjusted earnings per share also above expectations, leading to a 0.38% increase in stock price. On August 12, AbbVie announced a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S., boosting market confidence. On August 15, Point72 Hong Kong Ltd. initiated a position in AbbVie, indicating investor confidence in its future growth. Soleno Therapeutics fell 11.96%, with a trading volume of $169 million. Based on recent important news: On August 15, Scorpion Capital announced a short position on Soleno Therapeutics, pointing out issues with its new drug Vykat XR, causing a pre-market drop of 15%. On August 14, analysts predicted Soleno's Vykat XR sales to reach $413 million by 2027. On August 14, stocks of Soleno and Acadia rose following FDA approval of Vykat XR. Precigen rose 50%, with a trading volume of $152 million. Based on recent important news: On August 15, Precigen announced that its drug Papzimeos received full FDA approval, becoming the first treatment for recurrent respiratory papillomatosis, leading to a 34% increase in stock price. On August 15, HC Wainwright & Co. raised Precigen's target price from $6 to $8.50, further boosting the stock price. On August 15, Precigen began promoting Papzimeos, with stock price rising 44.32% in pre-market trading. Stocks with High Market Capitalization in the Industry Amgen rose 1.13%, with increased trading volume. Based on recent important news: On August 13, Amgen reported second-quarter results, with revenue up 9% year-over-year and net profit soaring 92%, exceeding market expectations, driving the stock price up 1.13% On August 14th, White House advisor Navarro mentioned pharmaceutical tariffs, causing Amgen's stock price to rise by 0.6% in response to the news. On August 13th, Bernstein lowered Amgen's target price to $335 but maintained an "outperform" rating, with limited market reaction